Omada Health, Inc.
Rank #72HypergrowthOMDA · Nasdaq · Healthcare
Omada Health, Inc. (OMDA) — Rank #72 by gross profitability (GP/assets 0.52) · ROE -5.1% · Piotroski F-Score 6 / 9.
As-of 2026-09-15 · CIK 0001611115 · all metrics point-in-time as of the filing date.
About
Omada Health, Inc., together with its subsidiary, Physera, Inc., provides a range of virtual care programs in the United States.
Show moreShow less
The company offers cardiometabolic programs for prediabetes, diabetes, and hypertension; a physical therapy program to address musculoskeletal conditions; other support programs for members taking glucagon-like peptide-1 agonists in its cardiometabolic program; and weight management programs, as well as various behavioral health support programs. It also delivers virtual care. The company offers its programs for employers, health plans and systems, and pharmacy benefits managers through its direct sales force and channel partners.
The company was incorporated in 2011 and is headquartered in South San Francisco, California.
- Industry
- Health Information Services
- Sector
- Healthcare
- State
- DE
- Filer Category
- Non-accelerated filerEmerging growth company
- Fiscal Year End
- December 31
- Website
- omadahealth.com
Financials
Stable
Direction over 5 fiscal years
- Free cash flowstable
- Gross marginstable
- Gross profitabilitystable
- Net cashstable
- Operating marginstable
- Return on equitystable
- Share count (dilution)stable
Monitoring diagnostic of business direction — not a prediction of returns.
Each fiscal year is read as-of that year’s own 10-K filing, so nothing restated after the fact leaks backwards. Line items this filer never tagged are omitted. Hover or tap a badge for the diagnostic behind it.
| Fiscal year end | 2025-12-31filed 2026-03-06 | 2024-12-31filed 2026-03-06 | 2023-12-31filed 2026-03-06 |
|---|---|---|---|
| Income statement | |||
| Revenue | 260.2 | 169.8 | 122.8 |
| Revenue growth (YoY) | 53.2% | 53.2% | 53.2% |
| Gross profit | 170.9 | 170.9 | 170.9 |
| Gross margin | 65.7% | 65.7% | 65.7% |
| Net income | (12.8) | (47.1) | (67.5) |
| Net margin | -4.9% | -4.9% | -4.9% |
| EPS (diluted) | -$0.35 | -$6.11 | -$9.52 |
| EPS growth (YoY) | 94.3% | 35.8% | — |
| Cash flow | |||
| Operating cash flow | 18.3 | (34.2) | (49.7) |
| Capital expenditures | 1.3 | — | — |
| Free cash flow | 16.9 | 16.9 | 16.9 |
Figures are as originally filed with the SEC (point-in-time), not restated, so they can differ slightly from sites that show later-restated numbers. Why point-in-time?